Genentech

May 31, 2017May 31, 2017

Pulmonary Fibrosis Foundation Says U.S. Database Now Has 1,000 PF Patients, Half of 2017 Enrollment Target

The Pulmonary Fibrosis Foundation (PFF) has announced that 1,000 Americans with pulmonary fibrosis (PF) have enrolled in its Patient Registry. The goal is to enroll another 1,000 patients by the end of 2017 ... Read more

May 25, 2017May 25, 2017

Esbriet Subgroup Analyses Suggest Benefits Also in Moderate and Severe IPF

Idiopathic Pulmonary Fibrosis, News

Patients with more severe idiopathic pulmonary fibrosis (IPF) also benefit from Esbriet (pirfenidone) treatment, as do IPF patients with moderate lung function impairment, according to two studies presented at the ... Read more

May 9, 2017May 9, 2017

Esbriet Lowers Risk of Respiratory-Related Hospitalizations in IPF Patients, Study Finds

Idiopathic Pulmonary Fibrosis, News

Patients under Esbriet (pirfenidone) treatment for idiopathic pulmonary fibrosis (IPF) have a lower risk of hospitalization due to respiratory symptoms or respiratory complications, researchers reported. The findings were published in the American Journal of ... Read more

October 24, 2016October 24, 2016

FDA Approves Tecentriq Immunotherapy for Specific Type of Advanced Lung Cancer

Lung Cancer, News

The U.S. Food and Drug Administration (FDA) approved Genentech’s Tecentriq (atezolizumab) as a treatment for people with metastatic non-small cell lung cancer (NSCLC). The drug is specifically indicated for NSCLC patients whose ... Read more

October 18, 2016October 18, 2016

Tecentriq for Lung Cancer Outperforms Conventional Chemotherapy, Increases Survival in Phase 3 Study

News

Genentech recently announced positive results from the pivotal Phase 3 OAK study (NCT02008227) demonstrating that its cancer immunotherapy Tecentriq (atezolizumab) is more effective than the chemotherapy Taxotere for increasing patients’ median overall survival. The findings were presented at ... Read more

September 23, 2016September 23, 2016

Genentech’s Tecentriq Seen to Significantly Increase Survival in Patients with Specific Type of Lung Cancer

Lung Cancer, News

Genentech recently announced positive results for its cancer immunotherapy Tecentriq (atezolizumab) being tested in the Phase 3 clinical trial OAK (NCT02008227). Tecentriq is a monoclonal antibody designed to bind to an immune checkpoint protein ... Read more

May 26, 2016May 26, 2016

Lung Cancer Drug Alecensa Shows Superior to Crizotinib, Study Indicates

News

The biotechnology company Genentech recently announced that its product Alecensa (alectinib) was superior in reducing disease worsening risk or death in a specific type of lung cancer, compared to treatment with crizotinib. Researchers measured the ... Read more

April 13, 2016April 13, 2016

Genentech’s Atezolizumab for Non-Small Cell Lung Cancer Gets FDA Nod for BLA and Priority Review

Lung Cancer, News

The U.S. Food and Drug Administration (FDA) has accepted Genentech’s Biologics License Application (BLA) and granted Priority Review for the company’s product atezolizumab for the treatment of locally advanced or ... Read more

March 7, 2016March 7, 2016

Two Phase 3 Trials for Asthma Drug Lebrikizumab Have Differing Results, Genentech Reports

Asthma, News

Genentech, a member of the Roche Group, recently reported top-line data from two Phase 3 clinical trials assessing the efficacy and safety of lebrikizumab in people with uncontrolled asthma despite ... Read more

March 4, 2016March 4, 2016

Genentech’s Application of Xolair for Allergic Asthma in Kids Is Under FDA Review

Asthma, News

Genentech recently announced that its supplemental Biologics License Application (sBLA) for extension of Xolair (omalizumab) in allergic asthma in pediatric patients has been accepted by the U.S. Food and Drug Administration (FDA). ... Read more